Sep. 17 at 2:34 PM
$CRVO Anyone have any insights on the status of RESTORE, and why the company hasn’t said much about it recently? Enrollment completion was announced July 9th with top line results expected H2 2026, but it’s been radio silence amongst other announcements. Every recent release prioritizes DLB results and partnership, nfvPPA, and EXPERTS-ALS. I figure maybe it’s because RESTORE will take longer, as is typical for this type of study, or maybe it’s getting slow walked because of cash constraints, or since stroke recovery is scientifically more speculative for this drug, maybe they want to keep expectations low so as not to spook investors (again) if it comes back negative?
